A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma
暂无分享,去创建一个
J. Vose | P. Abrisqueta | J. Tabernero | K. Papadopoulos | D. Rasco | A. Patnaik | K. Rajangam | K. Rockich | C. Egile | J. Lager | Yi Xu | G. Chambers | A. Kelly